**Summary of Current Week's News Sentiment:**

The overall sentiment of the news articles related to Dr. Reddy's Laboratories is **Positive**. The company has made several significant announcements, including the launch of Toripalimab, a drug to treat nasopharyngeal cancer, and Ivermectin Tablets USP, 3 mg in the US market. These launches have been well-received by the market, with most articles reporting a positive impact on the stock price.

**Notable Events:**

1. Launch of Toripalimab, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma in India.
2. Launch of Ivermectin Tablets USP, 3 mg in the US market.
3. Dr. Reddy's becomes the third country to access Toripalimab, a rare cancer treatment drug.

**News Tone:**

The news tone is **Positive**, with most articles highlighting the company's achievements and the potential benefits of its new launches. The language used is optimistic, with words like "launches", "first", "only", and "rare cancer treatment" creating a sense of excitement and innovation. The impact on the stock price is also reported to be positive, with most articles mentioning an increase in the stock price. Overall, the news tone suggests that Dr. Reddy's Laboratories is making significant progress in the pharmaceutical industry and is expected to continue to grow.